TEVA Announces Availability of Parkinson’s Disease Generic
by Allison Cerra – NORTH WALES, Pa. (Jan. 4) A generic drug maker has announced the availability of a treatment of the signs and symptoms of idiopathic Parkinson’s disease. Pramipexole diHCl tablets are available in a 0.125-mg strength, in a bottle size of 63, and in 0.25-mg, 0.5-mg, 1-mg, and 1.5-mg strengths, in bottle sizes of 90. The generic is equivalent to Mirapex, which was developed by Boehringer Ingelheim Pharmaceuticals. “Our customers count on Teva for a continuous supply of new generic products,” said Maureen Cavanaugh, VP customer operations and marketing. “With the launch of pramipexole dihydrochloride tablets, we add another quality product to our broad line of affordable generic pharmaceuticals.”
TEVA Announces Availability of Parkinson’s Disease Generic
by Allison Cerra – NORTH WALES, Pa. (Jan. 4) A generic drug maker has announced the availability of a treatment of the signs and symptoms of idiopathic Parkinson’s disease. Pramipexole diHCl tablets are available in a 0.125-mg strength, in a bottle size of 63, and in 0.25-mg, 0.5-mg, 1-mg, and 1.5-mg strengths, in bottle sizes of 90. The generic is equivalent to Mirapex, which was developed by Boehringer Ingelheim Pharmaceuticals. “Our customers count on Teva for a continuous supply of new generic products,” said Maureen Cavanaugh, VP customer operations and marketing. “With the launch of pramipexole dihydrochloride tablets, we add another quality product to our broad line of affordable generic pharmaceuticals.”
Posted in Boehringer Ingelheim Pharmaceuticals, Mirapex Generic, Parkinson's Disease, TEVA Pharmaceuticals Tagged: Boehringer Ingelheim Pharmaceuticals, Mirapex Generic, Parkinson's Disease Drugs, TEVA Pharmaceuticals